Oncologists debate the proper treatment of a patient with a grade 2 endometrial carcinoma tumor.
Bradley Monk, MD, FACOG, FACS
Advertisement
Articles by Bradley Monk, MD, FACOG, FACS
Physician-researchers discuss the risk of recurrence in endometrial carcinoma and the available treatment options after relapse.
An overview of biomarker testing in endometrial carcinoma.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Tucatinib Plus Trastuzumab/Pertuzumab as First-Line Maintenance in Advanced HER2+ Breast Cancer
2
FDA Grants Breakthrough Therapy Designation to Telisotuzumab Adizutecan Plus Bevacizumab in Refractory mCRC
3
Firmonertinib Fails to Meet PFS End Point in First-Line EGFR Exon 20 Insertion–Mutant NSCLC
4
FDA Grants Breakthrough Therapy Designation to Temab-A in Previously Treated c-Met–Expressing Nonsquamous NSCLC
5